GRAIL LLC
PANAMA CITY BEACH, FLORIDA

Jennifer Cook is the Chief Executive Officer of GRAIL. Previously, Jennifer was Head of Clinical Operations in Product Development for Roche Pharmaceuticals, where she managed a clinical trial portfolio of more than 400 trials with 100,000 participants. Before that she was Head of Region Europe for Roche Pharmaceuticals, where she was responsible for the commercial success of Europe and leading more than 5,500 employees across the 28 countries of the region. Jennifer started her career at Genentech in early-stage research and subsequently held numerous senior management positions covering the full lifecycle of product development and commercialization. Key positions included leading Product Portfolio Management, a U.S. Commercial Business Unit, and Market Development. In 2016, Jennifer was recognized for her contributions to the healthcare industry and inspirational leadership when she was named Woman of the Year by the Healthcare Businesswomen’s Association. Jennifer holds a BA in Human Biology and MS in Biology from Stanford University, as well as an MBA from the Haas School of Business at University of California, Berkeley. Ken Drazan, MD, is the President of GRAIL. Prior to GRAIL, Ken was Head of Johnson & Johnson’s California Innovation Centers. Ken was previously General Partner at Bertram Capital Management and CEO of Arginox Pharmaceuticals. Before that, he was Assistant Professor of Surgery/Liver Transplant at Stanford University Medical School, and a liver transplant surgeon at University of California, Los Angeles Medical Center. He holds a BA in Economics from Yale University and an MD from the State University of New York. Alex Aravanis, MD, PhD, is the Head of Research & Development at GRAIL. Prior to GRAIL, Alex developed multiple products at Illumina, including clinical assays for the analysis of RNA and DNA from fixed tissues, whole exome analysis, massively parallel single cell transcriptomics, and liquid biopsy using cell-free nucleic acids. Previously at Sapphire, Alex led development as its Chief Science Officer. Alex holds a PhD in Electrical Engineering and an MD from Stanford University. Charlotte Arnold is the Head of Corporate Communications at GRAIL. Prior to GRAIL, Charlotte was Vice President of Corporate Communications and Investor Relations at Relypsa. Before Relypsa, Charlotte worked at Genentech, where held several roles including leading communications for Genentech’s portfolio of cancer medicines, and communications regarding policy issues, managed care, pricing, distribution, and access. Charlotte is a board member of the San Francisco Bay Area Chapter of the Healthcare Businesswomen’s Association. Charlotte holds a BS in Physiology from the University of Bristol. Julie Ballard is the Director of CLIA Quality and Operations at GRAIL. As a licensed Clinical Laboratory Scientist, Julie is experienced in building and managing CLIA/CAP laboratories, quality, and regulatory programs. Prior to GRAIL, she led and played key roles in implementing novel diagnostic tests in clinical laboratories at Guardant Health, TOMA BioSciences, Genomic Health, and ViroLogic. Julie received a bachelor’s degree in Clinical Science from San Francisco State University and completed her CLS training at Stanford Medical Center. Patrick Broderick is General Counsel and Corporate Secretary at GRAIL. Prior to GRAIL, Patrick was General Counsel of McKesson Distribution Solutions at McKesson Corporation where he managed the legal teams supporting all of McKesson’s distribution businesses. Patrick holds a JD from Yale Law School where he was an editor of the Yale Law Journal, and a BA, summa cum laude, from Harvard College. Anne-Renee Hartman, MD, is the Head of Clinical Development at GRAIL. Prior to GRAIL, Anne-Renee was the Senior Vice President of Clinical Development at Myriad Genetics, where she led the development of several commercialized diagnostics in oncology. Anne-Renee was previously an Assistant Professor of Medicine at The Dana Farber Cancer Institute. She completed her oncology fellowship at Stanford where she helped set up the cancer genetics clinic. Anne-Renee holds a BS in Molecular Biology from Princeton University, an MD from The University of Michigan, and completed her residency in Internal Medicine at The University of Chicago. Angela Lai is the Head of Clinical Technology at GRAIL, leading the team of software engineers responsible for designing and building software systems to support clinical trials and diagnostic products. Previously, Angela was a Vice President at Google (2004-2016), where she led the Product and Engineering teams that developed Google products including AdWords, Wallet and Payment, and Search. Before Google, Angela founded and ran her own software development company. Angela holds BS degrees in Computer Engineering and Finance, and an MS in Computer Engineering from the University of Pennsylvania. Tara Maddala, PhD, is the Head of Biostatistics & Data Management at GRAIL. Prior to GRAIL, Tara led the Clinical Biostatistics team at Genomic Health responsible for design and analysis of large-scale oncology biomarker studies that resulted in algorithm-based commercial diagnostics. Before that, Tara was Director of Biostatistics at Clinimetrics. She holds an MS in Health Systems Engineering from Georgia Institue of Technology and a PhD in Biostatistics from The University of Texas. Elizabeth (Liz) Mansfield, PhD, is the Head of Regulatory Strategy at GRAIL. Prior to GRAIL, Liz was Deputy Office Director for Personalized Medicine and Director of the Personalized Medicine Staff in the Office of In Vitro Diagnostic Devices (OIVD) in the Center for Devices at the FDA, where she developed a program to address companion and novel diagnostic devices. She also previously served as a Senior Policy Analyst in OIVD, managing policy and scientific issues, and served in other positions at the FDA including Scientific Reviewer and Genetics Expert. Previously at Affymetrix, Liz was the Director of Regulatory Affairs (2004-2006). She holds a PhD from Johns Hopkins University and completed further postdoctoral training at the National Cancer Institute (NCI) and the National Institute for Arthritis, Musculoskeletal, and Skin Diseases (NIAMS).